3C Therapeutics Inc.
$84,000.00 CAD
≈ 13 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2025-2026
- Agreement period
- July 2, 2025 – March 31, 2026
- Reference
- nrc-cnrc:172-2025-2026-Q2-1032773
Published purpose
This project combines antibody-drug conjugates (ADCs) with targeted protein degradation (TPD) via PROTACs (proteolysis targeting chimeras) to create a Degrader-Antibody Conjugate (DAC) - a novel dual-precision therapeutic molecule.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions